$-1.27 EPS Expected for Loxo Oncology, Inc. (LOXO); Sharps Compliance (SMED) Has 1.57 Sentiment

February 13, 2018 - By Louis Casey

Analysts expect Loxo Oncology, Inc. (NASDAQ:LOXO) to report $-1.27 EPS on March, 6.They anticipate $0.01 EPS change or 0.78% from last quarter’s $-1.28 EPS. After having $-1.12 EPS previously, Loxo Oncology, Inc.’s analysts see 13.39% EPS growth. The stock increased 1.21% or $1.14 during the last trading session, reaching $95.08. About 18,959 shares traded. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 77.12% since February 13, 2017 and is uptrending. It has outperformed by 60.42% the S&P500.

Sharps Compliance Corp. provides medical, pharmaceutical, and hazardous waste management services in the United States. The company has market cap of $77.52 million. It offers Sharps Recovery System for the containment, transportation, treatment, and tracking of medical waste and used healthcare materials generated outside the hospital and health care facility settings; TakeAway Medication Recovery System, a solution that facilitates the proper disposal of unused medications; MedSafe, a solution for the safe collection, transportation, and proper disposal of unwanted and expired prescription medications; and ComplianceTRAC, a Web compliance and training program. It has a 602.5 P/E ratio. The firm also provides Route-Based Pickup Service, a waste management service, which offers medical and hazardous waste pick-up services; TakeAway Recycle System, a solution for the collection and recycling of single-use medical devices from surgical centers and other healthcare facilities; and Universal Waste Shipback Systems, a solution for the collection, transportation, and recycling of light bulbs, batteries, and other mercury containing devices.

Goodman Financial Corp holds 2.35% of its portfolio in Sharps Compliance Corp. for 1.01 million shares. Lapides Asset Management Llc owns 172,600 shares or 0.17% of their US portfolio. Moreover, Heartland Advisors Inc has 0.15% invested in the company for 493,429 shares. The Texas-based Ranger Investment Management L.P. has invested 0.14% in the stock. North Star Investment Management Corp., a Illinois-based fund reported 193,350 shares.

The stock decreased 0.41% or $0.02 during the last trading session, reaching $4.82. About 12 shares traded. Sharps Compliance Corp. (SMED) has risen 1.67% since February 13, 2017 and is uptrending. It has underperformed by 15.03% the S&P500.

Among 10 analysts covering Loxo Oncology Inc (NASDAQ:LOXO), 9 have Buy rating, 1 Sell and 0 Hold. Therefore 90% are positive. Loxo Oncology Inc had 30 analyst reports since July 29, 2015 according to SRatingsIntel. Morgan Stanley maintained the stock with “Buy” rating in Monday, June 19 report. Citigroup maintained Loxo Oncology, Inc. (NASDAQ:LOXO) on Friday, October 20 with “Buy” rating. The firm earned “Buy” rating on Monday, June 5 by Cowen & Co. The company was maintained on Friday, October 6 by Morgan Stanley. BTIG Research maintained the stock with “Buy” rating in Monday, June 5 report. Stifel Nicolaus maintained it with “Buy” rating and $104.0 target in Thursday, November 2 report. On Tuesday, November 14 the stock rating was upgraded by JMP Securities to “Buy”. On Wednesday, September 27 the stock rating was maintained by Stifel Nicolaus with “Buy”. Citigroup initiated it with “Buy” rating and $32 target in Monday, January 18 report. The stock of Loxo Oncology, Inc. (NASDAQ:LOXO) earned “Buy” rating by Jefferies on Wednesday, February 8.

Investors sentiment decreased to 1.73 in Q3 2017. Its down 2.10, from 3.83 in 2017Q2. It is negative, as 13 investors sold Loxo Oncology, Inc. shares while 35 reduced holdings. 31 funds opened positions while 52 raised stakes. 29.06 million shares or 49.34% less from 57.37 million shares in 2017Q2 were reported. State Common Retirement Fund has 25,097 shares for 0% of their portfolio. Ameriprise accumulated 127,266 shares or 0.01% of the stock. Advisory Research Inc owns 0.04% invested in Loxo Oncology, Inc. (NASDAQ:LOXO) for 29,961 shares. First Personal Fincl Svcs reported 400 shares. Regis Mgmt Limited Liability holds 0.05% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO) for 3,457 shares. Pictet Asset Mgmt reported 0.06% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO). Suffolk Cap Management Ltd Liability Corporation has 0.15% invested in Loxo Oncology, Inc. (NASDAQ:LOXO). Cornerstone Capital Holdings Ltd accumulated 9,200 shares. Prelude Capital Mngmt Ltd Liability Company accumulated 0% or 279 shares. 25,234 are owned by Rhumbline Advisers. Smith Asset Gp L P reported 4,430 shares. Rock Springs Cap Management Lp has invested 1.21% in Loxo Oncology, Inc. (NASDAQ:LOXO). Guggenheim Cap Limited Com has invested 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). State Street holds 0.01% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO) for 959,132 shares. Citigroup Inc owns 2,145 shares for 0% of their portfolio.

Since August 14, 2017, it had 0 insider purchases, and 18 insider sales for $70.60 million activity. $271,866 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) shares were sold by Van Naarden Jacob. Another trade for 15,000 shares valued at $1.50M was sold by Naider Avi Z.. ORBIMED ADVISORS LLC had sold 250,000 shares worth $20.63 million on Friday, December 8. $20.13M worth of Loxo Oncology, Inc. (NASDAQ:LOXO) shares were sold by AISLING CAPITAL III LP. Shares for $141,554 were sold by Burstein Jennifer on Thursday, December 14. On Monday, August 21 the insider Flaherty Keith T. sold $523,883. The insider Bonita David P sold 250,000 shares worth $20.63M.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>